Application of neurophysiological biomarkers for Huntington's disease: Evaluating a phosphodiesterase 9A inhibitor

Experimental Neurology

Volumn 263, Issue , 2015, Pages 122-131

  Nagy, Dávid ^a   Tingley, Francis D ^a   Stoiljkovic, Milan ^a   Hajós, Mihály ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Auditory gating; EEG; Huntington's disease; PF 04447943; Phosphodiesterase 9A

Indexed keywords

BIOLOGICAL MARKER; PF 04447943; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; 6-(4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-1-(TETRAHYDRO-2H-PYRAN-4-YL)-1,5-DIHYDRO-4H-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE; CYCLIC AMP PHOSPHODIESTERASE; ENZYME INHIBITOR; PDE9A PROTEIN, MOUSE; PDE9A PROTEIN, RAT; PYRAZOLE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG STRUCTURE; ELECTROENCEPHALOGRAM; EVOKED AUDITORY RESPONSE; FEMALE; HIPPOCAMPAL CA3 REGION; HUNTINGTON CHOREA; LOW DRUG DOSE; MALE; MOUSE; NERVE CELL NETWORK; NEUROPHYSIOLOGY; NONHUMAN; PRIMARY AUDITORY CORTEX; RAT; SENSORY GATING; TRANSGENIC ANIMAL; ANIMAL; ANTAGONISTS AND INHIBITORS; AUDITORY CORTEX; AUDITORY STIMULATION; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ELECTROPHYSIOLOGY; HIPPOCAMPUS; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE; TRANSGENIC RAT;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ACOUSTIC STIMULATION; ANIMALS; AUDITORY CORTEX; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; EVOKED POTENTIALS, AUDITORY; HIPPOCAMPUS; HUNTINGTON DISEASE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PYRAZOLES; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; SENSORY GATING;

EID: 84908681057     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.10.001     Document Type: Article

References (52)

1. Amann L.C., Gandal M.J., Halene T.B., Ehrlichman R.S., White S.L., McCarren H.S., Siegel S.J. Mouse behavioral endophenotypes for schizophrenia. Brain Res. Bull. 2010, 83(3-4):147-161.
2. Aurtenetxe S., Castellanos N.P., Moratti S., Bajo R., Gil P., Beitia G., del-Pozo F., Maestú F. Dysfunctional and compensatory duality in mild cognitive impairment during a continuous recognition memory task. Int. J. Psychophysiol. 2013, 87(1):95-102.
3. Azevedo M.F., Faucz F.R., Bimpak E., Horvath A., Levy I., de Alexandre R.B., Ahmad F., Manganiello V., Stratakis C.A. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr. Rev. 2014, 35(2):195-233.
4. Boutros N.N., Gjini K., Eickhoff S.B., Urbach H., Pflieger M.E. Mapping repetition suppression of the P50 evoked response to the human cerebral cortex. Clin. Neurophysiol. 2013, 124(4):675-685.
5. Browne S.E., Beal M.F. The energetics of Huntington's disease. Neurochem. Res. 2004, 29(3):531-546.
6. Buzsáki G., Wang X.J. Mechanisms of gamma oscillations. Annu. Rev. Neurosci. 2012, 35:203-225.
7. Chaturvedi R.K., Beal M.F. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Mol. Cell. Neurosci. 2013, 55:101-114. (Jul.).
8. Crook Z.R., Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69(3):423-435.
9. Di Stefano A., Sozio P., Cacciatore I., Cocco A., Giorgioni G., Costa B., Montali M., Lucacchini A., Martini C., Spoto G., Di Pietrantonio F., Di Matteo E., Pinnen F. Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists. J. Med. Chem. 2005, 48(7):2646-2654.
10. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., Cheng J.B. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 1998, 273(25):15559-15564.
11. Fisher S.P., Black S.W., Schwartz M.D., Wilk A.J., Chen T.M., Lincoln W.U., Liu H.W., Kilduff T.S., Morairty S.R. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease. Brain 2013, 136(Pt 7):2159-2172. (Jul.).
12. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 2007, Academic Press, New York. Third edition.
13. Gandal M.J., Edgar J.C., Ehrlichman R.S., Mehta M., Roberts T.P., Siegel S.J. Validating γ oscillations and delayed auditory responses as translational biomarkers of autism. Biol. Psychiatry 2010, 68(12):1100-1106.
14. Hajós M. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Trends Pharmacol. Sci. 2006, 27(7):391-398.
15. Hajós M., Hurst R.S., Hoffmann W.E., Krause M., Wall T.M., Higdon N.R., Groppi V.E. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther. 2005, 312(3):1213-1222.
16. Hajós M., Hoffmann W.E., Kocsis B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol. Psychiatry 2008, 63(11):1075-1083.
17. Harvey B.D., Siok C.J., Kiss T., Volfson D., Grimwood S., Shaffer C.L., Hajós M. Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors. Neuropharmacology 2013, 75C:19-30. (Epub ahead of print). 10.1016/j.neuropharm.2013.06.020.
18. Hebb A.L., Robertson H.A., Denovan-Wright E.M. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004, 123(4):967-981.
19. Hong L.E., Summerfelt A., Mitchell B.D., McMahon R.P., Wonodi I., Buchanan R.W., Thaker G.K. Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch. Gen. Psychiatry 2008, 65(9):1008-1016.
20. Hughes L.E., Rowe J.B. The impact of neurodegeneration on network connectivity: a study of change detection in frontotemporal dementia. J. Cogn. Neurosci. 2013, 25(5):802-813.
21. Hutson P.H., Finger E.N., Magliaro B.C., Smith S.M., Converso A., Sanderson P.E., Mullins D., Hyde L.A., Eschle B.K., Turnbull Z., Sloan H., Guzzi M., Zhang X., Wang A., Rindgen D., Mazzola R., Vivian J.A., Eddins D., Uslaner J.M., Bednar R., Gambone C., Le-Mair W., Marino M.J., Sachs N., Xu G., Parmentier-Batteur S. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 2011, 61(4):665-676.
22. Javitt D.C., Spencer K.M., Thaker G.K., Winterer G., Hajós M. Neurophysiological biomarkers for drug development in schizophrenia. Nat. Rev. Drug Discov. 2008, 7(1):68-83.
23. Jones N.C., Reddy M., Anderson P., Salzberg M.R., O'Brien T.J., Pinault D. Acute administration of typical and atypical antipsychotics reduces EEG γ power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in γ power. Int. J. Neuropsychopharmacol. 2012, 15(5):657-668.
24. Kantor S., Szabo L., Varga J., Cuesta M., Morton A.J. Progressive sleep and electroencephalogram changes in mice carrying the Huntington's disease mutation. Brain 2013, 136(Pt 7):2147-2158. (Jul.).
25. Kiss T., Feng J., Hoffmann W.E., Shaffer C.L., Hajós M. Rhythmic theta and delta activity of cortical and hippocampal neuronal networks in genetically or pharmacologically induced N-methyl-D-aspartate receptor hypofunction under urethane anesthesia. Neuroscience 2013, 237:255-267.
26. Kleiman R.J., Chapin D.S., Christoffersen C., Freeman J., Fonseca K.R., Geoghegan K.F., Grimwood S., Guanowsky V., Hajós M., Harms J.F., Helal C.J., Hoffmann W.E., Kocan G.P., Majchrzak M.J., McGinnis D., McLean S., Menniti F.S., Nelson F., Roof R., Schmidt A.W., Seymour P.A., Stephenson D.T., Tingley F.D., Vanase-Frawley M., Verhoest P.R., Schmidt C.J. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J. Pharmacol. Exp. Ther. 2012, 341(2):396-409.
27. Llinás R., Urbano F.J., Leznik E., Ramírez R.R., van Marle H.J. Rhythmic and dysrhythmic thalamocortical dynamics: GABA systems and the edge effect. Trends Neurosci. 2005, 28(6):325-333.
28. Loh D.H., Kudo T., Truong D., Wu Y., Colwell C.S. The Q175 mouse model of Huntington's disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep. PLoS One 2013, 8(7):e69993.
29. Menalled L., El-Khodor B.F., Hornberger M., Park L., Howland D., Brunner D. Effect of the rd1 mutation on motor performance in R6/2 and wild type mice. Version 2. PLoS 4:RRN1303 2012.
30. Menalled L., El-Khodor B.F., Patry M., Suárez-Fariñas M., Orenstein S.J., Zahasky B., Leahy C., Wheeler V., Yang X.W., MacDonald M., Morton A.J., Bates G., Leeds J., Park L., Howland D., Signer E., Tobin A., Brunner D. Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis. 2009, 35(3):319-336.
31. Mitsuishi M., Miyashita K., Itoh H. cGMP rescues mitochondrial dysfunction induced by glucose and insulin in myocytes. Biochem. Biophys. Res. Commun. 2008, 367(4):840-845. (Mar 21).
32. Moxon K.A., Gerhardt G.A., Gulinello M., Adler L.E. Inhibitory control of sensory gating in a computer model of the CA3 region of the hippocampus. Biol. Cybern. 2003, 88(4):247-264.
33. Mrzljak L., Munoz-Sanjuan I. Therapeutic strategies for Huntington's disease. Curr. Top. Behav. Neurosci. 2013, (Nov 27. [Epub ahead of print]) (in press).
34. Nguyen L., Bradshaw J.L., Stout J.C., Croft R.J., Georgiou-Karistianis N. Electrophysiological measures as potential biomarkers in Huntington's disease: review and future directions. Brain Res. Rev. 2010, 64(1):177-194.
35. Palop J.J., Chin J., Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006, 443(7113):768-773.
36. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, Sydney.
37. Russwurm M., Russwurm C., Koesling D., Mergia E. NO/cGMP: the past, the present, and the future. Methods Mol. Biol. 2013, 1020:1-16.
38. Saavedra A., Giralt A., Arumí H., Alberch J., Pérez-Navarro E. Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease. PLoS One 2013, 8(9):e73664.
39. Schmidt C.J., Chapin D.S., Cianfrogna J., Corman M.L., Hajós M., Harms J.F., Hoffman W.E., Lebel L.A., McCarthy S.A., Nelson F.R., Proulx-LaFrance C., Majchrzak M.J., Ramirez A.D., Schmidt K., Seymour P.A., Siuciak J.A., Tingley F.D., Williams R.D., Verhoest P.R., Menniti F.S. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 2008, 325(2):681-690.
40. Schulz S.B., Heidmann K.E., Mike A., Klaft Z.J., Heinemann U., Gerevich Z. First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors. Br. J. Pharmacol. 2012, 167(7):1480-1491.
41. Scott L., Feng J., Kiss T., Needle E., Atchison K., Kawabe T.T., Milici A.J., Hajós-Korcsok E., Riddell D., Hajós M. Age-dependent disruption in hippocampal θ oscillation in amyloid-β overproducing transgenic mice. Neurobiol. Aging 2012, 33(7). (1481.e13-23).
42. Steriade M. Grouping of brain rhythms in corticothalamic systems. Neuroscience 2006, 137(4):1087-1106.
43. Stevens K.E., Freedman R., Collins A.C., Hall M., Leonard S., Marks M.J., Rose G.M. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 1996, 15(2):152-162.
44. Thaker G.K. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr. Bull. 2008, 34(4):760-773.
45. Threlfell S., West A.R. Modulation of striatal neuron activity by cyclic nucleotide signalling and phosphodiesterase inhibition. Basal Ganglia 2013, 3(3):137-146.
46. Uc E.Y., Skinner R.D., Rodnitzky R.L., Garcia-Rill E. The midlatency auditory evoked potential P50 is abnormal in Huntington's disease. J. Neurol. Sci. 2003, 212(1-2):1-5.
47. Uhlhaas P.J., Pipa G., Neuenschwander S., Wibral M., Singer W. A new look at gamma? High- (>60Hz) γ-band activity in cortical networks: function, mechanisms and impairment. Prog. Biophys. Mol. Biol. 2011, 105(1-2):14-28.
48. Vardigan J.D., Converso A., Hutson P.H., Uslaner J.M. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. J. Neurogenet. 2011, 25(4):120-126.
49. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44(6):559-577.
50. Whitaker R.M., Wills L.P., Stallons L.J., Schnellmann R.G. cGMP-Selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury. J. Pharmacol. Exp. Ther. 2013, 347(3):626-634.
51. Yuen E.Y., Wei J., Zhong P., Yan Z. Disrupted GABAAR trafficking and synaptic inhibition in a mouse model of Huntington's disease. Neurobiol. Dis. 2012, 46(2):497-502.
52. Yu-Taeger L., Petrasch-Parwez E., Osmand A.P., Redensek A., Metzger S., Clemens L.E., Park L., Howland D., Calaminus C., Gu X., Pichler B., Yang X.W., Riess O., Nguyen H.P. A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. J. Neurosci. 2012, 32(44):15426-15438.